Date: August 16, 2022
Time: 7:00am PDT, 10:00am EDT, 4:00pm CEST, 4:00pm SAST
In this session, researchers, clinicians, and program implementers from four countries will address the disruption in continuity of care for PLHIV amid the COVID-19 pandemic and the consequent implications for drug resistance in individuals on ART. Panelists will highlight their country's progress to 90-90-90 goals pre-pandemic and discuss the current state-of-affairs in reaching the 2030 targets of 95-95-95. Key topics include: lessons learned from COVID-19 and their application to HIV patient monitoring and HIV drug resistance surveillance; opportunities to leverage HIV program structure to expand access to COVID-19 testing and vaccination; and recommended course of action to address gaps in care for PLHIV.
Gain insight on impact of COVID-19 pandemic on UNAIDs goals
Explore disruption in ART adherence and impact on emerging ART drug resistance mutations
Learn the state of HIV drug resistance for surveillance and patient management
Understand how to apply best practices gained from responding to COVID-19 on HIV patient monitoring and epidemiologic and genetic surveillance
Webinars will be available for unlimited on-demand viewing after live event.